Article
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.
American journal of hematology - 1 Jun 2026
Castillo Jorge J, Branagan Andrew R, Guijosa Alberto, von Keudell Gottfried, Ramirez-Gamero Andres, Chory Hannah, Kobs Margaret, Budano Nina, Nguyen Julia, Eurell Alexandra, Boyajian Courtney, Meid Kirsten, Guerrera Maria Luisa, Kofides Amanda, Liu Shirong, Liu Xia, Tsakmaklis Nicholas, Hunter Zachary R, Patterson Christopher J, Treon Steven P, Sarosiek Shayna
Abstract excerpt
The BTK inhibitor ibrutinib and the BCL-2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2-year fixed-duration, oral-based, chemotherapy-free regimen in symptomatic, treatment-naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.